Effect of Magnesium Sulphate on Neostigmine

NCT ID: NCT03020706

Last Updated: 2017-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

166 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effect of magnesium sulphate on neostigmine-induced reversal of neuromuscular block by rocuronium

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Comparison of reversa time by neostigmine in magnesium group and control group

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuromuscular Blockade

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Magnesium

magnesium sulfate, injectable intravenous administration (50mg/kg diluted in 100ml normal saline) during general anesthesia

Group Type EXPERIMENTAL

Magnesium Sulfate, Injectable

Intervention Type DRUG

magnesium sulphate intravenous administration during general anesthesia

Control

No intervention

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnesium Sulfate, Injectable

magnesium sulphate intravenous administration during general anesthesia

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

magnesium sulphate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA status 1 or 2
* patients undergoing surgery for more than 60 min under general anesthesia

Exclusion Criteria

* electrolyte abnormalities
* medication on aminoglycoside, antiepileptic drug, magnesium
* underweight or obesity (BMI \<18.5 or \>30)
* renal insufficiency (Cr\>1.4 mg/dl)
* AV block
* neuromuscular disease (ex: Myathenia gravis)
Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seoul National University Hospital

OTHER

Sponsor Role collaborator

Gachon University Gil Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Park Hee-Yeon

Associate professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sang-Hwan Do, MD, Ph D

Role: STUDY_CHAIR

Seoul National University Bundang Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Seoul National University Bundang Hospital

Seongnam, Kyungi-do, South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hee-Yeon Park, MD

Role: CONTACT

+82 10 3360 0790

Sang-Hwan Do, MD, Ph D

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hee-Yeon Park, MD

Role: primary

+82 10 3360 0790

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B-1610/367-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.